Abiomed announces enrollment of first patient in landmark RECOVER IV trial for AMI cardiogenic shock

Abiomed, part of Johnson & Johnson MedTech, announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).

Related Keywords

Japan ,United States ,Mexico ,Japanese ,Johnson Medtech ,Chuck Simonton ,Mark Bieniarz ,Drug Administration ,Mexico Heart Institute ,National Cardiogenic Shock Initiative ,Abiomed ,United States Food ,Inova Study ,New Mexico Heart Institute ,New Mexico Heart ,Kansas City Cardiomyopathy Questionnaire ,Cardiogenic Shock ,Wood ,Health Care ,Healthcare ,Heart ,Myocardial Infarction ,Research ,Surgery ,Technology ,